Loading clinical trials...
Loading clinical trials...
Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant
Conditions
Interventions
Melphalan
Pegfilgrastim
+1 more
Locations
1
United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
September 1, 2016
Primary Completion Date
September 1, 2026
Completion Date
September 1, 2026
Last Updated
October 10, 2025
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT06138275
NCT05862012
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions